Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
Shares of NuVasive, Inc. (NASDAQ:NUVA - Get Rating) have received a consensus recommendation of "Hold" from the fifteen analysts that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, six have given a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $61.75.
A number of brokerages have recently weighed in on NUVA. Piper Sandler reduced their price objective on shares of NuVasive from $80.00 to $60.00 and set an "overweight" rating on the stock in a report on Thursday, August 4th. Morgan Stanley dropped their target price on shares of NuVasive from $62.00 to $54.00 and set an "equal weight" rating on the stock in a research report on Friday, July 15th. Canaccord Genuity Group increased their target price on shares of NuVasive from $50.00 to $55.00 in a research report on Friday, August 5th. Finally, Truist Financial dropped their target price on shares of NuVasive to $63.00 in a research report on Friday, July 22nd.Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. Verition Fund Management LLC acquired a new stake in shares of NuVasive in the 2nd quarter worth $507,000. Captrust Financial Advisors lifted its stake in shares of NuVasive by 20.4% in the 2nd quarter. Captrust Financial Advisors now owns 2,539 shares of the medical device company's stock worth $125,000 after acquiring an additional 431 shares during the period. Castleark Management LLC lifted its stake in shares of NuVasive by 8.8% in the 2nd quarter. Castleark Management LLC now owns 106,460 shares of the medical device company's stock worth $5,234,000 after acquiring an additional 8,610 shares during the period. Woodline Partners LP lifted its stake in shares of NuVasive by 102.6% in the 2nd quarter. Woodline Partners LP now owns 665,010 shares of the medical device company's stock worth $32,692,000 after acquiring an additional 336,741 shares during the period. Finally, Thrivent Financial for Lutherans lifted its stake in shares of NuVasive by 7.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 2,184,893 shares of the medical device company's stock worth $107,409,000 after acquiring an additional 149,346 shares during the period. NuVasive Price Performance
Shares of NUVA opened at $43.35 on Friday. NuVasive has a twelve month low of $41.33 and a twelve month high of $64.43. The firm's fifty day simple moving average is $49.86 and its 200-day simple moving average is $52.38. The firm has a market capitalization of $2.26 billion, a price-to-earnings ratio of -54.19, a PEG ratio of 1.74 and a beta of 1.14. The company has a current ratio of 1.17, a quick ratio of 0.70 and a debt-to-equity ratio of 0.54. NuVasive Company Profile (Get Rating)
NuVasive, Inc, a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment.Featured StoriesGet a free copy of the StockNews.com research report on NuVasive (NUVA)Could Snap Stock Rebound As Management Restructures?MarketBeat: Week in Review 8/29 – 9/2Hormel Looks Cheap At These Levels Lululemon Set To Soar Into SeptemberCould Nike Stock be Oversold, but Still Overvalued?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider NuVasive, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NuVasive wasn't on the list.
While NuVasive currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:
Michael Wang of Prometheus Alternative Investments discusses how individuals should approach their portfolios as the summer rally seems to have fizzled.
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.